U.S. Markets closed
  • S&P Futures

    3,604.50
    +28.50 (+0.80%)
     
  • Dow Futures

    29,819.00
    +273.00 (+0.92%)
     
  • Nasdaq Futures

    11,972.25
    +67.00 (+0.56%)
     
  • Russell 2000 Futures

    1,838.50
    +21.40 (+1.18%)
     
  • Crude Oil

    43.51
    +0.45 (+1.05%)
     
  • Gold

    1,821.90
    -15.90 (-0.87%)
     
  • Silver

    23.41
    -0.22 (-0.94%)
     
  • EUR/USD

    1.1854
    +0.0008 (+0.0711%)
     
  • 10-Yr Bond

    0.8570
    +0.0280 (+3.38%)
     
  • Vix

    22.66
    -1.04 (-4.39%)
     
  • GBP/USD

    1.3333
    +0.0011 (+0.0813%)
     
  • USD/JPY

    104.5200
    +0.0320 (+0.0306%)
     
  • BTC-USD

    18,391.61
    +59.10 (+0.32%)
     
  • CMC Crypto 200

    370.00
    +8.57 (+2.37%)
     
  • FTSE 100

    6,333.84
    -17.61 (-0.28%)
     
  • Nikkei 225

    26,226.56
    +699.19 (+2.74%)
     

IFF Reports Third Quarter 2020 Results

·20 min read

Regulatory News:

International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF) reported financial results for the third quarter ended September 30, 2020.

Third Quarter 2020 Consolidated Summary:

Reported

(GAAP)

Adjusted

(Non-GAAP)1

Sales

Operating

Profit

EPS

Sales

Operating

Profit

EPS

EPS ex

Amortization

$1.3 B

$150 M

$0.75

$1.3 B

$193 M

$1.06

$1.40

First Nine Months 2020 Consolidated Summary:

Reported

(GAAP)

Adjusted

(Non-GAAP)1

Sales

Operating

Profit

EPS

Sales

Operating

Profit

EPS

EPS ex

Amortization

$3.8 B

$466 M

$2.64

$3.8 B

$574 M

$3.38

$4.39

¹ Schedules at the end of this release contain reconciliations of reported GAAP to non-GAAP metrics.

Management Commentary

"Despite the COVID-19 related headwinds, we achieved a strong sequential improvement in our financial results in the third quarter," said Andreas Fibig, IFF Chairman and CEO. "Our business continues to be resilient, growing 3% excluding the impact of Fine Fragrance and Food Service, led by a third consecutive quarter of robust growth in Consumer Fragrance. Fine Fragrance and Food Service improved relative to the second quarter, yet still declined as a result of COVID-19.

IFF Executive Vice President and CFO, Rustom Jilla commented, "From a profitability perspective, we have also seen a sequential improvement in the third quarter even as we continued to incur higher pandemic related operating costs. The focus on cash remained intense with lower working capital days and higher free cash flow – both sequentially and versus the prior year. Looking ahead to the fourth quarter, while the level of COVID-19 uncertainty remains too high to provide guidance, we face a roughly 400 basis point sales headwind solely as a result of 2019’s fourth quarter which included an additional week of sales."

Andreas Fibig concluded, "We also made great progress towards our combination with DuPont Nutrition and Biosciences. To date, we have received antitrust clearance in nearly all markets, obtained overwhelming approval from our shareholders and, in conjunction with N&B successfully completed the permanent financing, including a $6.25 billion senior notes offering at attractive interest rates. While there are a few remaining items, including outstanding regulatory approvals, we continue to expect to complete the merger in the first quarter of 2021."

Third Quarter 2020 Consolidated Financial Results

  • Reported net sales for the third quarter were $1.27 billion, flat when compared to the prior year period. Currency neutral sales increased 1%, representing a sequential improvement versus the second quarter, with year-over-year growth driven by Scent. Fine Fragrance and Food Service, impacted most as a result of the COVID-19 pandemic, improved relative to their second quarter performance, yet declined 14% on a currency neutral basis or 15% on a reported basis. The rest of the portfolio, excluding Fine Fragrance and Food Service was solid, growing 3% on both a currency neutral and reported basis.

  • Reported operating profit for the third quarter was $150.3 million, a decrease of 19% from $184.7 million in 2019. Adjusted operating profit excluding amortization increased 1% on a currency neutral basis as margin improvement in Scent was offset by challenges in Taste.

  • Reported earnings per share (EPS) for the third quarter was $0.75 per diluted share versus $1.13 per diluted share reported in 2019. Adjusted EPS excluding amortization was $1.40 per diluted share in 2020 versus $1.53 in the year-ago period as the devaluation of emerging market currencies versus the US dollar and Euro adversely impacted Other Income/Expense. On a currency neutral basis, adjusted EPS excluding amortization increased 1% driven primarily by adjusted operating profit performance.

Third Quarter 2020 Segment Summary1: Growth vs. Prior Year

Reported
(GAAP)

Currency Neutral
(Non-GAAP)

Sales

Segment
Profit

Sales

Segment
Profit

Scent

4%

15%

4%

20%

Taste

(2)%

(16)%

(1)%

(13)%

1 Starting in the first quarter 2020, IFF reports financial results in two segments, Taste and Scent, incorporating nearly all of the Frutarom business into the Taste segment.

Scent Segment

  • On a reported basis, sales increased 4% to $502.8 million, and 4% on a currency neutral basis. Consumer Fragrance growth remained strong, increasing double-digits both on a reported and currency neutral basis, with growth across nearly all sub-categories. Fine Fragrance experienced a marked sequential improvement versus the second quarter, yet declined mid-teens on a reported and currency neutral basis due to the temporary disruptions of consumer access to retail markets related to COVID-19. Fragrance Ingredients returned to growth in the third quarter led by double-digit growth in Cosmetic Actives, both on a reported and currency neutral basis.

  • Scent segment profit increased 15% on a reported basis and 20% on a currency neutral basis led primarily by higher sales volume and strong benefits of productivity initiatives.

Taste Segment

  • On a reported basis, sales decreased 2% to $765.2 million, or declined 1% on a currency neutral basis. Food Service, while improved versus the second quarter, experienced continued pressure, declining double-digits on a reported and currency neutral basis. The rest of the portfolio excluding Food Service was solid, growing low single-digits on a currency neutral basis and flat on a reported basis. From a geographic perspective, North America increased double-digits, with growth in nearly all categories. In EAME, growth was challenged primarily by pressures in Savory Solutions while Latin America and Greater Asia continued to be impacted by COVID-19.

  • Taste segment profit decreased 16% on a reported basis and 13% on a currency neutral basis principally as acquisition-related synergies were more than offset by lower sales volume, unfavorable price versus input costs and higher COVID-19 related costs.

Financial Guidance

As the COVID-19 pandemic continues to evolve, there is uncertainty around its ultimate impact. Therefore, the Company's full year financial results cannot be reasonably estimated at this time.

For the fourth quarter of 2020, the prior year comparison included an additional week of sales or a 53rd week, which represented approximately 4 percentage points of currency neutral sales as disclosed in the fourth quarter 2019.

Audio Webcast

A live webcast to discuss the Company’s third quarter 2020 financial results will be held on November 10, 2020, at 10:00 a.m. ET. The webcast and accompanying slide presentation may be accessed on the Company's IR website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available on the Company's website approximately one hour after the event and will remain available on IFF’s website for one year.

Cautionary Statement Under The Private Securities Litigation Reform Act of 1995

This press release includes "forward-looking statements" under the Federal Private Securities Litigation Reform Act of 1995, including statements regarding the expected impact of the COVID-19 pandemic on the Company’s near term results, expectations regarding sales and profit for the fourth quarter of 2020, the volatility of the economic environment and uncertainty about the duration and impact of the COVID-19 pandemic; revenue from its categories with retail channel exposure, such as Fine Fragrance and Food Service; the expected impact of the COVID-19 pandemic on the global economy; the Company’s ability to manage through the COVID-19 pandemic and to mitigate the near-term impact; the Company’s expectations regarding growth in the Taste segment in the medium-term; and the Company’s expectations regarding the proposed combination with N&B. These forward-looking statements are qualified in their entirety by cautionary statements and risk factor disclosures contained in the Company’s Securities and Exchange Commission ("SEC") filings, including the Company’s Annual Report on Form 10-K filed with the SEC on March 3, 2020, Quarterly Report on Form 10-Q filed with the SEC on May 11, 2020 and subsequent filings with the SEC. The Company wishes to caution readers that certain important factors may have affected and could in the future affect the Company’s actual results and could cause the Company’s actual results for subsequent periods to differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. With respect to the Company’s expectations regarding these statements, such factors include, but are not limited to: (1) the effect of economic conditions in the industries and markets in which IFF operates in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand, the impact of weather conditions, natural disasters, public health issues, epidemics and pandemics, including the novel coronavirus (COVID-19), or the fear of such events, and the financial condition of IFF’s customers and suppliers; (2) the risks to the Company’s business from the COVID-19 pandemic, including operational risks, supply chain risks, and customer related-risks; (3) risks related to the integration of the Frutarom business, including whether the Company will realize the benefits anticipated from the acquisition in the expected time frame; (4) unanticipated costs, liabilities, charges or expenses resulting from the Frutarom acquisition; (5) the impact of the outcome of legal claims, regulatory investigations and litigation; (6) the increase in the Company’s leverage resulting from the additional debt incurred to pay a portion of the consideration for Frutarom and its impact on the Company’s liquidity and ability to return capital to its shareholders; (7) the Company’s ability to successfully market to its expanded and decentralized Taste and Frutarom customer base; (8) the Company’s ability to effectively compete in its market and develop and introduce new products that meet customers’ needs; (9) the Company’s ability to successfully develop innovative and cost-effective products that allow customers to achieve their own profitability expectations; (10) the impact of a disruption in the Company’s manufacturing operations; (11) the impact of a disruption in the Company’s supply chain, including the inability to obtain ingredients and raw materials from third parties; (12) volatility and increases in the price of raw materials, energy and transportation; (13) the Company’s ability to comply with, and the costs associated with compliance with, regulatory requirements and industry standards, including regarding product safety, quality, efficacy and environmental impact; (14) the impact of any failure or interruption of the Company’s key information technology systems or a breach of information security; (15) the Company’s ability to react in a timely and cost-effective manner to changes in consumer preferences and demands; (16) the Company’s ability to establish and manage collaborations, joint ventures or partnership that lead to development or commercialization of products; (17) the Company’s ability to benefit from its investments and expansion in emerging markets; (18) the impact of currency fluctuations or devaluations in the principal foreign markets in which it operates; (19) economic, regulatory and political risks associated with the Company’s international operations; (20) the impact of global economic uncertainty on demand for consumer products; (21) the inability to retain key personnel; (22) the Company’s ability to comply with, and the costs associated with compliance with, U.S. and foreign environmental protection laws; (23) the Company’s ability to realize the benefits of its cost and productivity initiatives; (24) the Company’s ability to successfully manage its working capital and inventory balances; (25) the impact of the failure to comply with U.S. or foreign anti-corruption and anti-bribery laws and regulations, including the U.S. Foreign Corrupt Practices Act; (26) the Company’s ability to protect its intellectual property rights; (27) the impact of the outcome of legal claims, regulatory investigations and litigation; (28) changes in market conditions or governmental regulations relating to the Company’s pension and postretirement obligations; (29) the impact of future impairment of the Company’s tangible or intangible long-lived assets; (30) the impact of changes in federal, state, local and international tax legislation or policies, including the Tax Cuts and Jobs Act, with respect to transfer pricing and state aid, and adverse results of tax audits, assessments, or disputes; (31) the effect of potential government regulation on certain product development initiatives, and restrictions or costs that may be imposed on the Company or its operations as a result; and (32) the impact of the United Kingdom’s departure from the European Union. New risks emerge from time to time and it is not possible for management to predict all such risk factors or to assess the impact of such risks on the Company’s business. Accordingly, the Company undertakes no obligation to publicly revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Use of Non-GAAP Financial Measures

We provide in this press release non-GAAP financial measures, including: (i) currency neutral sales; (ii) adjusted operating profit; (iii) adjusted operating profit (margin) ex. amortization; (iv) adjusted EPS; (v) adjusted EPS ex. amortization and (vi) currency neutral adjusted EPS ex amortization.

Our non-GAAP financial measures are defined below.

Currency Neutral metrics eliminate the effects that result from translating international currency to U.S. dollars. We calculate currency neutral numbers by comparing current year results to the prior year results restated at exchange rates in effect for the current year based on the currency of the underlying transaction.

Adjusted Operating Profit excludes the impact of operational improvement initiatives, integration related costs, restructuring and other charges, net, losses (gains) on sale of assets, FDA mandated product recall, Frutarom acquisition related costs, compliance review & legal defense costs, and N&B transaction related costs ("Operating Profit Items Impacting Comparability").

Adjusted Operating Profit (Margin) ex. Amortization excludes the impact of Operating Profit Items Impacting Comparability and the amortization of acquisition related intangible assets.

Adjusted EPS excludes the impact of operational improvement initiatives, acquisition related costs, integration related costs, restructuring and other charges, net, losses (gains) on sale of assets, FDA mandated product recall, Frutarom acquisition related costs, compliance review & legal defense costs, N&B transaction related costs, and redemption value adjustment to EPS (often referred to as "Items Impacting Comparability").

Adjusted EPS ex. Amortization excludes the impact of Items Impacting Comparability and the amortization of acquisition related intangible assets.

These non-GAAP measures are intended to provide additional information regarding our underlying operating results and comparable year-over-year performance. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. In discussing our historical and expected future results and financial condition, we believe it is meaningful for investors to be made aware of and to be assisted in a better understanding of, on a period-to-period comparable basis, financial amounts both including and excluding these identified items, as well as the impact of exchange rate fluctuations. These non-GAAP measures should not be considered in isolation or as substitutes for analysis of the Company’s results under GAAP and may not be comparable to other companies’ calculation of such metrics.

In the fourth quarter of fiscal year 2018, we began including Adjusted EPS ex. Amortization as a key non-GAAP financial measure of our business. Full amortization expense of intangible assets acquired in connection with acquisitions will be excluded from Adjusted EPS ex. Amortization calculation. The exclusion of amortization expense allows comparison of operating results that are consistent over time for newly and long-held businesses and with both acquisitive and non-acquisitive peer companies. We believe this calculation will provide a more accurate presentation in this and in future periods in the event of additional acquisitions. Further, this allows the investors to evaluate and understand operating trends excluding the impact on operating income and earnings per diluted share. In addition, the Frutarom acquisition related costs and N&B transaction related costs have been separated from costs related to prior acquisitions. The Frutarom acquisition related costs and N&B transaction related costs represent a significant balance and we believe this amount should be shown separately to provide an accurate presentation of the acquisition related costs. Our GAAP results and GAAP metrics do not change, and this change has no effect on day to day business operations, or how we manage our business.

Welcome to IFF

At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at www.iff.com, Twitter, Facebook, Instagram, and LinkedIn.

International Flavors & Fragrances Inc.

Consolidated Income Statement

(Amounts in thousands except per share data)

(Unaudited)

Three Months Ended September 30,

Nine Months Ended September 30,

2020

2019

% Change

2020

2019

% Change

Net sales

$

1,268,076

$

1,267,345

%

$

3,814,166

$

3,856,315

(1)

%

Cost of goods sold

743,649

734,257

1

%

2,242,030

2,245,729

%

Gross profit

524,427

533,088

(2)

%

1,572,136

1,610,586

(2)

%

Research and development expenses

89,968

85,077

6

%

256,825

260,489

(1)

%

Selling and administrative expenses

234,520

210,829

11

%

694,641

634,111

10

%

Amortization of acquisition-related intangibles

47,738

48,430

(1)

%

144,922

143,964

1

%

Restructuring and other charges, net

1,497

3,716

(60)

%

8,299

22,415

(63)

%

Losses on sales of fixed assets

415

372

12

%

1,568

1,136

38

%

Operating profit

150,289

184,664

(19)

%

465,881

548,471

(15)

%

Interest expense

34,844

33,497

4

%

99,046

102,662

(4)

%

Other expense (income), net

9,945

(5,699

)

NMF

4,762

(15,114

)

NMF

Income before taxes

105,500

156,866

(33)

%

362,073

460,923

(21)

%

Taxes on income

19,269

27,059

(29)

%

61,265

81,033

(24)

%

Net income

86,231

129,807

(34)

%

300,808

379,890

(21)

%

Net income attributable to noncontrolling interest

1,403

2,683

(48)

%

5,169

7,560

(32)

%

Net income attributable to IFF

84,828

127,124

(33)

%

295,639

372,330

(21)

%

Net income per share - basic (1)

$

0.76

$

1.15

$

2.68

$

3.34

Net income per share - diluted (1)

$

0.75

$

1.13

$

2.64

$

3.30

Average number of shares outstanding - basic

112,183

111,998

112,148

111,953

Average number of shares outstanding - diluted

113,622

113,493

113,631

113,133

(1)

For 2020 and 2019, net income per share reflects adjustments related to the redemption value of certain redeemable noncontrolling interests.

NMF Not meaningful

International Flavors & Fragrances Inc.

Condensed Consolidated Balance Sheet

(Amounts in thousands)

(Unaudited)

September 30,

December 31,

2020

2019

Cash, cash equivalents, and restricted cash

$

482,681

$

623,945

Receivables

928,625

876,197

Inventories

1,151,281

1,123,068

Other current assets

383,618

319,334

Total current assets

2,946,205

2,942,544

Property, plant and equipment, net

1,380,423

1,386,920

Goodwill and other intangibles, net

8,102,964

8,349,531

Other assets

655,782

608,416

Total assets

13,085,374

13,287,411

Short term borrowings

$

440,962

$

384,958

Other current liabilities

1,175,297

1,167,232

Total current liabilities

1,616,259

1,552,190

Long-term debt

3,890,762

3,997,438

Non-current liabilities

1,388,033

1,409,192

Redeemable noncontrolling interests

100,005

99,043

Shareholders' equity

6,090,315

6,229,548

Total liabilities and shareholders' equity

$

13,085,374

$

13,287,411

International Flavors & Fragrances Inc.

Consolidated Statement of Cash Flows

(Amounts in thousands)

(Unaudited)

Nine Months Ended September 30,

2020

2019

Cash flows from operating activities:

Net income

$

300,808

$

379,890

Adjustments to reconcile to net cash provided by operating activities

Depreciation and amortization

243,576

235,429

Deferred income taxes

(37,146

)

(35,134

)

Losses on sale of assets

1,568

1,136

Stock-based compensation

27,177

26,426

Pension contributions

(18,901

)

(16,390

)

Changes in assets and liabilities, net of acquisitions:

Trade receivables

(94,292

)

(22,878

)

Inventories

(42,771

)

(84,140

)

Accounts payable

21,593

(39,332

)

Accruals for incentive compensation

19,033

(20,726

)

Other current payables and accrued expenses

59,962

(12,161

)

Other assets

(72,886

)

(58,016

)

Other liabilities

7,307

28,931

Net cash provided by operating activities

415,028

383,035

Cash flows from investing activities:

Cash paid for acquisitions, net of cash received

(49,065

)

Additions to property, plant and equipment

(124,070

)

(160,449

)

Additions to intangible assets

(6,070

)

Proceeds from life insurance contracts

1,739

1,890

Maturity of net investment hedges

(14,597

)

Proceeds from disposal of assets

18,202

34,607

Proceeds from unwinding of cross currency swap derivative instruments

25,900

Contingent consideration paid

(4,655

)

Net cash used in investing activities

(118,726

)

(157,842

)

Cash flows from financing activities:

Cash dividends paid to shareholders

(240,273

)

(233,477

)

(Decrease) increase in revolving credit facility and short term borrowings

(655

)

11

Deferred financing costs

(3,205

)

Repayments on debt

(335,084

)

(100,785

)

Purchases of redeemable noncontrolling interest

(21,566

)

Proceeds from issuance of long-term debt

200,000

Contingent consideration paid

(9,562

)

(21,791

)

Proceeds from issuance of stock in connection with stock options

200

Employee withholding taxes paid

(7,664

)

(9,966

)

Net cash used in financing activities

(418,009

)

(365,808

)

Effect of exchange rates changes on cash, cash equivalents and restricted cash

(18,712

)

(3,853

)

Net change in cash, cash equivalents and restricted cash

(140,419

)

(144,468

)

Cash, cash equivalents and restricted cash at beginning of year

623,945

648,522

Cash, cash equivalents and restricted cash at end of period

$

483,526

$

504,054

The following table reconciles cash, cash equivalents and restricted cash between the Company's statement of cash flows for the periods ended September 30, 2020 and September 30, 2019 to the amounts reported in the Company's balance sheet:

September 30, 2020

December 31, 2019

September 30, 2019

December 31, 2018

Current assets

Cash and cash equivalents

$

469,840

$

606,823

$

494,897

$

634,897

Restricted cash

12,841

17,122

9,157

13,625

Noncurrent assets

Restricted cash included in Other assets

845

Cash, cash equivalents and restricted cash

$

483,526

$

623,945

$

504,054

$

648,522

International Flavors & Fragrances Inc.

Business Unit Performance

(Amounts in thousands)

(Unaudited)

Three Months Ended September 30,

Nine Months Ended September 30,

2020

2019

2020

2019

Net Sales

Taste

$

765,238

$

782,428

$

2,343,884

$

2,398,549

Scent

502,838

484,917

1,470,282

1,457,766

Consolidated

$

1,268,076

$

1,267,345

$

3,814,166

$

3,856,315

Segment Profit

Taste

$

101,600

$

121,425

$

346,223

$

383,450

Scent

101,388

87,894

277,156

272,061

Global Expenses

(9,608

)

(8,385

)

(49,550

)

(35,957

)

Operational Improvement Initiatives

(712

)

(1,652

)

Frutarom Integration Related Costs

(1,883

)

(10,511

)

(8,816

)

(36,825

)

Restructuring and Other Charges, net

(1,497

)

(3,716

)

(8,299

)

(22,415

)

Losses on sale of assets

(415

)

(372

)

(1,568

)

(1,136

)

FDA Mandated Product Recall

(250

)

(250

)

Frutarom Acquisition Related Costs

(808

)

2,914

(1,382

)

(5,182

)

Compliance Review & Legal Defense Costs

(1,000

)

(3,623

)

(1,624

)

(3,623

)

N&B Transaction Related Costs

(8,247

)

(24,372

)

N&B Integration Related Costs

(29,241

)

(61,887

)

Operating profit

150,289

184,664

465,881

548,471

Interest Expense

(34,844

)

(33,497

)

(99,046

)

(102,662

)

Other (expense) income, net

(9,945

)

5,699

(4,762

)

15,114

Income before taxes

$

105,500

$

156,866

$

362,073

$

460,923

Operating Margin

Taste

13

%

16

%

15

%

16

%

Scent

20

%

18

%

19

%

19

%

Consolidated

12

%

15

%

12

%

14

%

International Flavors & Fragrances Inc.

GAAP to Non-GAAP Reconciliation

Foreign Exchange Impact

(Unaudited)

Q3 Taste

Sales

Segment
Profit

% Change - Reported

(2)%

(16)%

Currency Impact

1%

3%

% Change - Currency Neutral

(1)%

(13)%

Q3 Scent

Sales

Segment
Profit

% Change - Reported

4%

15%

Currency Impact

0%

5%

% Change - Currency Neutral

4%

20%

Q3 Consolidated

Sales

Adjusted

Operating Profit

EPS ex.

Amortization

% Change - Adjusted (Non-GAAP)

0%

(3)%

(9)%

Currency Impact

1%

4%

10%

% Change - Currency Neutral

1%

1%

1%

YTD Taste

Sales

Segment
Profit

% Change - Reported

(2)%

(10)%

Currency Impact

2%

3%

% Change - Currency Neutral

0%

(7)%

YTD Scent

Sales

Segment
Profit

...

% Change - Reported

1%

2%

Currency Impact

1%

2%

% Change - Currency Neutral

2%

4%

YTD Consolidated

Sales

Adjusted

Operating Profit

EPS ex.

Amortization

% Change - Adjusted (Non-GAAP)

(1)%

(6)%

(7)%

Currency Impact

2%

2%

5%

% Change - Currency Neutral

1%

(4)%

(2)%

International Flavors & Fragrances Inc.
GAAP to Non-GAAP Reconciliation
(Unaudited)

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

Reconciliation of Gross Profit

Third Quarter

(DOLLARS IN THOUSANDS)

2020

2019

Reported (GAAP)

$

524,427

$

533,088

Operational Improvement Initiatives (a)

711

Frutarom Integration Related Costs (c)

103

187

FDA Mandated Product Recall (e)

250

Frutarom Acquisition Related Costs (f)

(3,603

)

Adjusted (Non-GAAP)

$

524,530

$

530,633

Reconciliation of Selling and Administrative Expenses

Third Quarter

(DOLLARS IN THOUSANDS)

2020

2019

Reported (GAAP)

$

234,520

$

210,829

Frutarom Integration Related Costs (c)

(1,597

)

(10,047

)

Frutarom Acquisition Related Costs (f)

(808

)

(691

)

Compliance Review & Legal Defense Costs (g)

(1,000

)

(3,623

)

N&B Transaction Related Costs (h)

(8,247

)

N&B Integration Related Costs (i)

(29,241

)

Adjusted (Non-GAAP)

$

193,627

$

196,468

Reconciliation of Operating Profit

Third Quarter

(DOLLARS IN THOUSANDS)

2020

2019

Reported (GAAP)

$

150,289

$

184,664

Operational Improvement Initiatives (a)

712

Frutarom Integration Related Costs (c)

1,883

10,511

Restructuring and Other Charges, net (d)

1,497

3,716

Losses on Sale of Assets

415

372

FDA Mandated Product Recall (e)

250

Frutarom Acquisition Related Costs (f)

808

(2,914

)

Compliance Review & Legal Defense Costs (g)

1,000

3,623

N&B Transaction Related Costs (h)

8,247

N&B Integration Related Costs (i)

29,241

Adjusted (Non-GAAP)

$

193,380

$

200,934

Reconciliation of Adjusted (Non-GAAP) Operating Profit Margin ex. Amortization

(DOLLARS IN THOUSANDS)

Third Quarter

Numerator

2020

2019

Adjusted (Non-GAAP) Operating Profit

$

193,380

$

200,934

Amortization of Acquisition related Intangible Assets

47,738

48,430

Adjusted (Non-GAAP) Operating Profit ex. Amortization

241,118

249,364

Denominator

Sales

1,268,076

1,267,345

Adjusted (Non-GAAP) Operating Profit Margin ex. Amortization

19.0

%

19.7

%

International Flavors & Fragrances Inc.
GAAP to Non-GAAP Reconciliation
(Unaudited)

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

Reconciliation of Net Income

Third Quarter

2020

2019

(DOLLARS IN THOUSANDS)

Income

before

taxes

Taxes on

income

(k)

Net Income

Attributable

to IFF (l)

Diluted

EPS

(m)

Income

before

taxes

Taxes on

income

(k)

Net Income

Attributable to

IFF (l)

Diluted

EPS

(m)

Reported (GAAP)

$

105,500

$

19,269

$

84,828

$

0.75

$

156,866

$

27,059

$

127,124

$

1.13

Operational Improvement Initiatives (a)

712

243

469

Acquisition Related Costs (b)

(3,371

)

(3,371

)

(0.03

)

Frutarom Integration Related Costs (c)

1,883

407

1,476

0.01

10,511

2,347

8,164

0.07

Restructuring and Other Charges, net (d)

1,497

349

1,148

0.01

3,716

811

2,905

0.03

Losses on Sale of Assets

415

91

324

372

98

274

FDA Mandated Product Recall (e)

250

57

193

Frutarom Acquisition Related Costs (f)

1,316

523

793

0.01

(2,914

)

(715

)

(2,199

)

(0.02

)

Compliance Review & Legal Defense Costs (g)

1,000

228

772

0.01

3,623

827

2,796

0.02

N&B Transaction Related Costs (h)

8,247

8,247

0.07

N&B Integration Related Costs (i)

29,241

6,719

22,522

0.20

Redemption value adjustment to EPS (j)

(0.01

)

(0.02

)

Adjusted (Non-GAAP)

$

149,099

$

27,586

$

120,110

$

1.06

$

169,765

$

30,727

$

136,355

$

1.20

Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization

Third Quarter

(DOLLARS AND SHARE AMOUNTS IN THOUSANDS)

2020

2019

Numerator

Adjusted (Non-GAAP) Net Income

$

120,110

$

136,355

Amortization of Acquisition related Intangible Assets

47,738

48,430

Tax impact on Amortization of Acquisition related Intangible Assets (k)

8,564

10,961

Amortization of Acquisition related Intangible Assets, net of tax (n)

39,174

37,469

Adjusted (Non-GAAP) Net Income ex. Amortization

159,284

173,824

Denominator

Weighted average shares assuming dilution (diluted)

113,622

113,493

Adjusted (Non-GAAP) EPS ex. Amortization

$

1.40

$

1.53

(a)

Represents accelerated depreciation related to a plant relocation in India and China.

(b)

Represents adjustments to the fair value for an equity method investment in Canada which we began consolidating in the second quarter of 2019.

(c)

Represents costs related to the integration of the Frutarom acquisition. For 2020, costs primarily related to advisory services, retention bonuses and performance stock awards. For 2019, costs principally related to advisory services.

(d)

For 2020, represents costs primarily related to the Frutarom Integration Initiative. For 2019, represents costs primarily related to the Frutarom Integration Initiative and 2019 Severance Program.

(e)

Represents additional claims that management paid to co-packers.

(f)

Represents transaction-related costs and expenses related to the acquisition of Frutarom. For 2020, amount primarily includes earn-out payments, net of adjustments, amortization for inventory "step-up" costs and transaction costs principally related to the 2019 Acquisition Activity, including an adjustment to reverse an earnout liability and another adjustment to record an earnout liability in the third quarter of 2020. For 2019, amount primarily includes amortization for inventory "step-up" costs and transaction costs, along with a measurement period adjustment to the amount of the inventory "step-up" recorded.

(g)

Costs related to reviewing the nature of inappropriate payments and review of compliance in certain other countries. In addition, includes legal costs for related shareholder lawsuits.

(h)

Represents transaction costs and expenses related to the pending transaction with N&B, principally related to legal and professional fees for capital raising activities.

(i)

Represents costs primarily related to advisory services for the integration of the pending transaction with N&B, principally consulting fees.

(j)

Represents the adjustment to EPS related to the excess of the redemption value of certain redeemable noncontrolling interests over their existing carrying value.

(k)

The income tax expense (benefit) on non-GAAP adjustments is computed in accordance with ASC 740 using the same methodology as the GAAP provision of income taxes. Income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for each jurisdiction in which such charges were incurred, except for those items which are non-taxable or are subject to a valuation allowance for which the tax expense (benefit) was calculated at 0%. For fiscal years 2020 and 2019, these non-GAAP adjustments were not subject to foreign tax credits, but to the extent that such factors are applicable to any future non-GAAP adjustments we will take such factors into consideration in calculating the tax expense (benefit). For amortization, the tax benefit has been calculated based on the statutory rate on a country by country basis.

(l)

For 2020 and 2019, net income is reduced by income attributable to noncontrolling interest of $1.4M and $2.7M, respectively.

(m)

The sum of these items does not foot due to rounding.

(n)

Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax.

International Flavors & Fragrances Inc.
GAAP to Non-GAAP Reconciliation
(Unaudited)

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

Reconciliation of Gross Profit

Third Quarter Year-to-Date

(DOLLARS IN THOUSANDS)

2020

2019

Reported (GAAP)

$

1,572,136

$

1,610,586

Operational Improvement Initiatives (a)

1,651

Frutarom Integration Related Costs (c)

348

508

FDA Mandated Product Recall (e)

250

Frutarom Acquisition Related Costs (f)

759

4,247

Adjusted (Non-GAAP)

$

1,573,243

$

1,617,242

Reconciliation of Selling and Administrative Expenses

Third Quarter Year-to-Date

(DOLLARS IN THOUSANDS)

2020

2019

Reported (GAAP)

$

694,641

$

634,111

Frutarom Integration Related Costs (c)

(7,875

)

(35,647

)

Frutarom Acquisition Related Costs (f)

(623

)

(937

)

Compliance Review & Legal Defense Costs (g)

(1,624

)

(3,623

)

N&B Transaction Related Costs (h)

(24,372

)

N&B Integration Related Costs (i)

(61,887

)

Adjusted (Non-GAAP)

$

598,260

$

593,904

Reconciliation of Operating Profit

Third Quarter Year-to-Date

(DOLLARS IN THOUSANDS)

2020

2019

Reported (GAAP)

$

465,881

$

548,471

Operational Improvement Initiatives (a)

1,652

Frutarom Integration Related Costs (c)

8,816

36,825

Restructuring and Other Charges, net (d)

8,299

22,415

Losses on Sale of Assets

1,568

1,136

FDA Mandated Product Recall (e)

250

Frutarom Acquisition Related Costs (f)

1,382

5,182

Compliance Review & Legal Defense Costs (g)

1,624

3,623

N&B Transaction Related Costs (h)

24,372

N&B Integration Related Costs (i)

61,887

Adjusted (Non-GAAP)

$

573,829

$

619,554

Reconciliation of Adjusted (Non-GAAP) Operating Profit Margin ex. Amortization

(DOLLARS IN THOUSANDS)

Third Quarter Year-to-Date

Numerator

2020

2019

Adjusted (Non-GAAP) Operating Profit

$

573,829

$

619,554

Amortization of Acquisition related Intangible Assets

144,922

143,964

Adjusted (Non-GAAP) Operating Profit ex. Amortization

718,751

763,518

Denominator

Sales

3,814,166

3,856,315

Adjusted (Non-GAAP) Operating Profit Margin ex. Amortization

18.8

%

19.8

%

International Flavors & Fragrances Inc.
GAAP to Non-GAAP Reconciliation
(Unaudited)

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

Reconciliation of Net Income

Third Quarter Year-to-Date

2020

2019

(DOLLARS IN THOUSANDS)

Income

before

taxes

Taxes on

income

(k)

Net Income

Attributable to

IFF (l)

Diluted

EPS

(m)

Income

before

taxes

Taxes on

income

(k)

Net Income

Attributable to

IFF (l)

Diluted

EPS

Reported (GAAP)

$

362,073

$

61,265

$

295,639

$

2.64

$

460,923

$

81,033

$

372,330

$

3.30

Operational Improvement Initiatives (a)

1,652

561

1,091

0.01

Acquisition Related Costs (b)

(3,371

)

(3,371

)

(0.03

)

Frutarom Integration Related Costs (c)

8,816

1,959

6,857

0.06

36,825

8,270

28,555

0.25

Restructuring and Other Charges, net (d)

8,299

1,922

6,377

0.06

22,415

5,394

17,021

0.16

Losses on Sale of Assets

1,568

356

1,212

0.01

1,136

290

846

0.01

FDA Mandated Product Recall (e)

250

57

193

Frutarom Acquisition Related Costs (f)

1,382

(1,160

)

2,542

0.02

5,182

672

4,510

0.04

Compliance Review & Legal Defense Costs (g)

1,624

358

1,266

0.01

3,623

827

2,796

0.02

N&B Transaction Related Costs (h)

24,372

904

23,468

0.21

N&B Integration Related Costs (i)

61,887

14,255

47,632

0.42

Redemption value adjustment to EPS (j)

(0.04

)

(0.02

)

Adjusted (Non-GAAP)

$

470,021

$

79,859

$

384,993

$

3.38

$

528,635

$

97,104

$

423,971

$

3.74

Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization

Third Quarter Year-to-Date

(DOLLARS AND SHARE AMOUNTS IN THOUSANDS)

2020

2019

Numerator

Adjusted (Non-GAAP) Net Income

$

384,993

$

423,971

Amortization of Acquisition related Intangible Assets

144,922

143,964

Tax impact on Amortization of Acquisition related Intangible Assets (k)

30,635

33,792

Amortization of Acquisition related Intangible Assets, net of tax (n)

114,287

110,172

Adjusted (Non-GAAP) Net Income ex. Amortization

499,280

534,143

Denominator

Weighted average shares assuming dilution (diluted)

113,631

113,133

Adjusted (Non-GAAP) EPS ex. Amortization

$

4.39

$

4.72

(a)

Represents accelerated depreciation related to a plant relocation in India and China.

(b)

Represents adjustments to the fair value for an equity method investment in Canada which we began consolidating in the second quarter of 2019.

(c)

Represents costs related to the integration of the Frutarom acquisition. For 2020, costs primarily related to advisory services, retention bonuses and performance stock awards. For 2019, costs principally related to advisory services.

(d)

For 2020, represents costs primarily related to the Frutarom Integration Initiative. For 2019, represents costs primarily related to the Frutarom Integration Initiative and 2019 Severance Program.

(e)

Represents additional claims that management paid to co-packers.

(f)

Represents transaction-related costs and expenses related to the acquisition of Frutarom. For 2020, amount primarily includes earn-out payments, net of adjustments, amortization for inventory "step-up" costs and transaction costs principally related to the 2019 Acquisition Activity, including an adjustment to reverse an earnout liability and another adjustment to record an earnout liability in the third quarter of 2020. For 2019, amount primarily includes amortization for inventory "step-up" costs and transaction costs, along with a measurement period adjustment to the amount of the inventory "step-up" recorded.

(g)

Costs related to reviewing the nature of inappropriate payments and review of compliance in certain other countries. In addition, includes legal costs for related shareholder lawsuits.

(h)

Represents transaction costs and expenses related to the pending transaction with N&B, principally related to legal and professional fees for capital raising activities.

(i)

Represents costs primarily related to advisory services for the integration of the pending transaction with N&B, principally consulting fees.

(j)

Represents the adjustment to EPS related to the excess of the redemption value of certain redeemable noncontrolling interests over their existing carrying value.

(k)

The income tax expense (benefit) on non-GAAP adjustments is computed in accordance with ASC 740 using the same methodology as the GAAP provision of income taxes. Income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for each jurisdiction in which such charges were incurred, except for those items which are non-taxable or are subject to a valuation allowance for which the tax expense (benefit) was calculated at 0%. For fiscal years 2020 and 2019, these non-GAAP adjustments were not subject to foreign tax credits, but to the extent that such factors are applicable to any future non-GAAP adjustments we will take such factors into consideration in calculating the tax expense (benefit). For amortization, the tax benefit has been calculated based on the statutory rate on a country by country basis.

(l)

For 2020 and 2019, net income is reduced by income attributable to noncontrolling interest of $5.2M and $7.6M, respectively.

(m)

The sum of these items does not foot due to rounding.

(n)

Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201109006129/en/

Contacts

Michael DeVeau
Head of Investor Relations and Communications
212.708.7164
Michael.DeVeau@iff.com